NCT00631878View on ClinicalTrials.gov

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

May 31, 2003

Study Completion Date

August 31, 2003

Conditions
Neonatal Staphylococcal Sepsis
Interventions
DRUG

Pagibaximab (formerly BSYX-A110)

Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Biosynexus Incorporated

INDUSTRY